Your session is about to expire
← Back to Search
Capecitabine for Advanced Breast Cancer
Study Summary
This trial is comparing the effectiveness of two different doses of capecitabine in treating women who have advanced or metastatic breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had radiation on my cancer spots unless they've grown.I haven't taken any experimental drugs in the last 4 weeks and am not currently in another cancer study.I've had 2-3 chemotherapy treatments, including one with paclitaxel and an anthracycline.My liver function tests are within the required limits and I don't have hepatitis.My kidney function tests are within the required range.I am a woman aged 18 or older.My cancer has not spread to my brain.My cancer's hormone receptor status is not determined.I have not had any organ transplants.I am mostly able to care for myself and carry out daily activities.My breast cancer is confirmed and has spread beyond the breast.My heart is healthy with no significant diseases or recent heart attacks.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many locations are currently running this experiment?
"The trial is operational in 13 different medical sites, with the major facilities located at Charleston Hematology-Oncology (South carolina), Oncology Clinic (Colorado Springs), and Maryland Hematology/Oncology Associates (Baltimore)."
Are there any vacancies to partake in this clinical investigation?
"Unfortunately, the trial is no longer recruiting as per information on clinicaltrials.gov; this study was initially published in November 2001 and last updated December 2013. However, there are 2,600 other trials searching for patients at present."
Does this treatment pose any safety risks for those who use it?
"This treatment is estimated to be moderately safe, as indicated by its rating of 2. This assessment was determined based on the Phase 2 trial which provided data regarding safety but lacked proof of efficacy."
Share this study with friends
Copy Link
Messenger